Antidepressant Can Change Patient's Personality

Dec 07, 2009 By Megan Fellman

(PhysOrg.com) -- The nation is still debating the effects of antidepressant medications on brain chemistry almost 20 years after publication of the best-seller "Listening to Prozac." Though selective serotonin reuptake inhibitors (SSRIs) are widely used to treat depression today, understanding of their mechanisms remains limited.

Now a new study led by a Northwestern University psychologist shows for the first time that an antidepressant medication can change patient personality substantially. Those personality changes are also linked to significantly better long-term improvements in mood.

The findings will be published in the December issue of , one of the JAMA/Archives journals.

"Our findings lead us to propose a new model of antidepressant mechanism," said Tony Z. Tang, adjunct professor of psychology in the Weinberg College of Arts and Sciences at Northwestern. "Our data suggests that modern antidepressants work partly by correcting key personality risk factors of depression."

Tang and colleagues studied the effects of the SSRI paroxetine (Paxil and Seroxat) in a placebo-controlled trial involving 240 adults with major depressive disorder. As typical in such clinical trials, patients taking paroxetine experienced moderately greater depression improvement than those receiving placebo. However, individuals taking paroxetine experienced a far greater decrease in neuroticism and an increase in extraversion than those receiving placebo.

Neuroticism and extraversion are two fundamental personality dimensions extracted from empirical analyses of human languages. Neuroticism refers to a tendency to experience negative emotions and emotional instability, whereas extraversion refers not only to socially outgoing behavior but also to dominance and a tendency to experience positive emotions.

Several lines of recent research converged on the key importance of these personality dimensions: high neuroticism is a key risk factor of depression; twin studies also have found substantial overlap in the genes associated with high neuroticism and the genes associated with depression; and both neuroticism and extraversion are associated with the brain's serotonin system, which is targeted by SSRI antidepressants.

In this study, 120 participants were randomly assigned to take paroxetine. Another 60 were randomly assigned to undergo cognitive therapy. Their personalities and depressive symptoms were assessed before, during and after treatment. After treatment, the 69 paroxetine responders were followed for a year to assess depression relapse.

Patients taking paroxetine reported 6.8 times as much change on neuroticism and 3.5 times as much change on extraversion as placebo patients matched for depression improvement.

The findings provide evidence against the common assumption that personality changes during SSRI treatment occur only as a byproduct of alleviating depressive symptoms, the authors note. Several alternative explanations could be considered.

"One possibility is that the biochemical properties of SSRIs directly produce real personality change," the authors write. "Furthermore, because neuroticism is an important risk factor that captures much of the genetic vulnerability for , change in neuroticism (and in neurobiological factors underlying neuroticism) might have contributed to depression improvement."

In this study, the advantage of paroxetine over placebo in changing personality appears far more drastic than its advantage over placebo in alleviating depression. SSRIs also can effectively treat many anxiety disorders and eating disorders, conditions for which high neuroticism and low extraversion may also be key risk factors. "Investigating how SSRIs affect neuroticism and extraversion may thus lead toward a more parsimonious understanding of the mechanisms of SSRIs," the authors conclude. SSRIs perhaps can be viewed as personality-normalizing agents, useful in treating many disorders associated with high neuroticism and low extraversion.

The paper is titled " Change During Treatment: A Placebo-Controlled Trial." In addition to Tang, other authors of the paper are Benjamin Schalet, of Northwestern; Robert J. DeRubeis and Jay Amsterdam, of the University of Pennsylvania; and Steven D. Hollon and Richard Shelton, of Vanderbuilt University.

The National Institute of Mental Health supported the research. GlaxoSmithKline of Brentford, England, provided medications and placebo pills.

Provided by Northwestern University (news : web)

Explore further: Self-regulation intervention boosts school readiness of at-risk children, study shows

add to favorites email to friend print save as pdf

Related Stories

Researchers identify personality traits

Apr 03, 2009

Researchers from Boston University School of Medicine's (BUSM) New England Centenarian Study have noted specific personality traits associated with healthy aging and longevity amongst the children of centenarians. The work ...

Recommended for you

Brains transform remote threats into anxiety

18 hours ago

Modern life can feel defined by low-level anxiety swirling through society. Continual reports about terrorism and war. A struggle to stay on top of family finances and hold onto jobs. An onslaught of news ...

Mental disorders due to permanent stress

19 hours ago

Activated through permanent stress, immune cells will have a damaging effect on and cause changes to the brain. This may result in mental disorders. The effects of permanent stress on the immune system are studied by the ...

Could there be a bright side to depression?

20 hours ago

(Medical Xpress)—A group of researchers studying the roots of depression has developed a test that leads them closer to the idea that depression may actually be an adaptation meant to help people cope with ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.